TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6440186

Group type: EXPERIMENTAL
Intervention: CR (Contingent Reward)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: IO (Information Only)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NCR (Noncontingent Reward)
Number of subjects: 24

Group type: COMPARATOR
Intervention: NR (No Reward)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (session 5)
Number of subjects: 24
Study: 30095230

Group type: EXPERIMENTAL
Intervention: PASS Plus
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 40
Study: 30103735

Group type: EXPERIMENTAL
Intervention: Fortified food
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Syrup
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Micronutrient powders
Number of subjects: 0
Study: 27171733

Group type: COMPARATOR
Intervention: MacIntosh
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: KVL
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Airtraq®
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: GlideScope®
Number of subjects: 21
Study: 25528834

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI) escitalopram
Number of subjects: 0
Study: 22710821

Group type: EXPERIMENTAL
Intervention: recombinant human Cu/Zn superoxide dismutase (rhSOD)
Number of subjects: 302

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 302
Study: 20478877

Group type: EXPERIMENTAL
Intervention: Medication switch alone (alternate SSRI or venlafaxine)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Medication switch plus cognitive‐behavioral therapy (CBT)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Responders by week 12
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Nonresponders by week 12
Number of subjects: 334
Study: 19085343

Group type: EXPERIMENTAL
Intervention: Aliskiren/HCT 300/25 mg
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Aliskiren/HCT 300/12.5 mg
Number of subjects: 880

Group type: COMPARATOR
Intervention: Aliskiren 300 mg monotherapy
Number of subjects: 880
Study: 15905733

Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 33
Study: 12881590

Group type: EXPERIMENTAL
Intervention: Oral carbenoxolone (CBX), an inhibitor of 11beta‐HSD, administered to patients with ocular hypertension.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral carbenoxolone (CBX), an inhibitor of 11beta‐HSD, administered to healthy volunteers.
Number of subjects: 0
Study: 10320172

Group type: EXPERIMENTAL
Intervention: Intraperitoneal lidocaine (0.5% in 80 mL)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both IM morphine (10 mg in 1 mL) and intraperitoneal lidocaine (0.5% in 80 mL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: IM morphine (10 mg in 1 mL) and intraperitoneal isotonic sodium chloride solution (80 mL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: IM isotonic sodium chloride solution (1 mL) and intraperitoneal isotonic sodium chloride solution (80 mL)
Number of subjects: 80
Study: 10172702

Group type: EXPERIMENTAL
Intervention: Phone intervention provided to 19 subjects
Number of subjects: 354

Group type: COMPARATOR
Intervention: Control group (2 subjects who refused intervention)
Number of subjects: 354
Study: 1888692

Group type: EXPERIMENTAL
Intervention: Sublingual administration of 20 mg of ketanserin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Oral administration of 20 mg of ketanserin
Number of subjects: 37
Study: 29480185

Group type: EXPERIMENTAL
Intervention: Internet-based multidomain intervention for cardiovascular risk management
Number of subjects: 2500
Study: 28487911

Group type: EXPERIMENTAL
Intervention: Ziyinqingre prescription (Chinese Traditional Medicine), administered twice a day for two weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Montelukast Sodium tablets, 10mg once a day for two weeks (Control)
Number of subjects: 84
Study: 24263469

Group type: EXPERIMENTAL
Intervention: 100 mL Turkish coffee (57 mg caffeine/100 mL)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 62
Study: 22640678

Group type: EXPERIMENTAL
Intervention: Sydney Magnoglide and comprehensive fixed appliance therapy
Number of subjects: 34
Study: 20604657

Group type: EXPERIMENTAL
Intervention: Pulmonary recruitment manoeuvre (5 manual inflations of the lungs with positive pressure ventilation of 40 cmH(2)O at the end of surgery)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Traditional passive deflation of abdominal cavity (Control)
Number of subjects: 146
Study: 18339561

Group type: EXPERIMENTAL
Intervention: Modified Waddell approach
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Seated anteromedial approach
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lateral patellar approach
Number of subjects: 50
Study: 15764779

Group type: EXPERIMENTAL
Intervention: Potassium dichromate C30 globules, 5 globules administered twice daily at intervals of 12 h
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 12444480

Group type: EXPERIMENTAL
Intervention: Association between size and colour of square blocks (e.g. red = large; yellow = small)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consistent kinematic conditions (blocks presented in the same location)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Variable kinematic conditions (blocks presented in different locations)
Number of subjects: 0
Study: 10524887

Group type: EXPERIMENTAL
Intervention: Holmium laser resection
Number of subjects: 120

Group type: COMPARATOR
Intervention: Transurethral prostatic resection
Number of subjects: 120
Study: 7717643

Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac
Number of subjects: 60

Group type: COMPARATOR
Intervention: Opioid analgesia
Number of subjects: 60
Study: 1786194

Group type: EXPERIMENTAL
Intervention: CQ plus PSK
Number of subjects: 103

Group type: COMPARATOR
Intervention: CQ alone
Number of subjects: 103
Study: 6128722

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 54

Group type: COMPARATOR
Intervention: Nitrazepam
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 54
Study: 29528443

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) with 20 to 40 Gy of low-energy photons in addition to standard radiochemotherapy
Number of subjects: 15
Study: 30083727

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention using telephone‐delivered behavioral interviewing by trained clinical pharmacists, text messaging, pillboxes, and mailed progress reports.
Number of subjects: 4078

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4078

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 4078
Study: 25838271

Group type: EXPERIMENTAL
Intervention: MIP + TTC
Number of subjects: 48

Group type: COMPARATOR
Intervention: MIP alone
Number of subjects: 48
Study: 24439651

Group type: EXPERIMENTAL
Intervention: Chamomile Extract 100 mg three times a day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Mefenamic acid (MA) 250 mg three times a day
Number of subjects: 90
Study: 22846235

Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 36

Group type: COMPARATOR
Intervention: No-alcohol beverage
Number of subjects: 36
Study: 19460655

Group type: EXPERIMENTAL
Intervention: 16-week e-mail program with individually tailored, small-step goals; personal homepage with tips; educational materials; tracking and simulation tools
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: 16-week e-mail program
Number of subjects: 787
Study: 16612619

Group type: EXPERIMENTAL
Intervention: Biodegradable cement restrictor
Number of subjects: 130

Group type: COMPARATOR
Intervention: Non-degradable cement restrictor
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 130
Study: 14520142

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 152

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 152
Study: 10972367

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 10881

Group type: COMPARATOR
Intervention: Diuretics and beta-blockers
Number of subjects: 10881
Study: 8849401

Group type: EXPERIMENTAL
Intervention: Atherosclerotic women (n = 34)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Nonatherosclerotic women (n = 79)
Number of subjects: 113
Study: 1296494

Group type: EXPERIMENTAL
Intervention: Optiray 300
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iopamiron 370
Number of subjects: 0
Study: 6500777

Group type: EXPERIMENTAL
Intervention: Vincamine teprosilate (1 ampoule i.v.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (1 ampoule i.v.)
Number of subjects: 10
Study: 31956931

Group type: EXPERIMENTAL
Intervention: 27G vitrectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: 25G vitrectomy
Number of subjects: 60
Study: 31324354

Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Periarticular Infiltration (PAI)
Number of subjects: 100
Study: 27995346

Group type: EXPERIMENTAL
Intervention: Deep breathing (stress Intervention Functional IFA)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control Group (no treatment)
Number of subjects: 38
Study: 26070341

Group type: EXPERIMENTAL
Intervention: Unfavorable EEG pattern at 24 hours
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Absent pupillary light responses at 48 hours
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Absent somatosensory evoked potentials at 72 hours
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Unfavorable EEG patterns at 12 hours, absent or extensor motor response to pain at 72 hours, and higher age
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Favorable EEG patterns at 12 hours
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: EEG beyond 24 hours
Number of subjects: 277
Study: 23842856

Group type: EXPERIMENTAL
Intervention: Tamoxifen followed by exemestane
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: UGT2B15*2
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: ESR1 PvuII polymorphism
Number of subjects: 731
Study: 21623000

Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate (TNF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DMARD methotrexate, sulphasalazine and hydroxychloroquine in combination (COMBO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Methotrexate alone (MTX)
Number of subjects: 60
Study: 20047115

Group type: EXPERIMENTAL
Intervention: Rosiglitazone plus metformin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Glimepiride plus metformin
Number of subjects: 34
Study: 16510745

Group type: EXPERIMENTAL
Intervention: Natalizumab plus interferon beta-1a
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Placebo (interferon beta-1a alone)
Number of subjects: 1171
Study: 14749551

Group type: EXPERIMENTAL
Intervention: Zinograf
Number of subjects: 18

Group type: COMPARATOR
Intervention: Neoral
Number of subjects: 18
Study: 11236120

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 62

Group type: COMPARATOR
Intervention: Single dose systemic methotrexate (50 mg/m2)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Comparison of treatment success rates
Number of subjects: 62

Group type: COMPARATOR
Intervention: Physical functioning scores
Number of subjects: 62

Group type: COMPARATOR
Intervention: Ipsilateral tubal patency rates
Number of subjects: 62
Study: 9605644

Group type: EXPERIMENTAL
Intervention: Granulocyte colony‐stimulating factor (G‐CSF) (lenograstim; 5 microg/kg body weight per day subcutaneously)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control (no G‐CSF)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Granulocyte colony‐stimulating factor (G‐CSF)
Number of subjects: 149
Study: 7998486

Group type: EXPERIMENTAL
Intervention: Intravenous nimodipine, 2 mg per hour for 7 days
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study: 3194342

Group type: EXPERIMENTAL
Intervention: roxithromycin (150 mg b.i.d.)
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study: 30358242

Group type: EXPERIMENTAL
Intervention: Venlafaxine treatment (12 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 28762072

Group type: EXPERIMENTAL
Intervention: D-amphetamine (20 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 26218228

Group type: EXPERIMENTAL
Intervention: Direct treatment (Lidcombe Program)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Indirect treatment (RESTART-DCM treatment)
Number of subjects: 199
Study: 23054851

Group type: EXPERIMENTAL
Intervention: Oil massage along with standard care of low birth weight
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard care of low birth weight without massage
Number of subjects: 48
Study: 20878861

Group type: EXPERIMENTAL
Intervention: Multidisciplinary quality of life (MQOL) intervention (n=30)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Wait list control (n=27)
Number of subjects: 57
Study: 18801158

Group type: EXPERIMENTAL
Intervention: Community promotion in addition to IPTp-SP (Intervention A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly chloroquine (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IPTp-SP (Intervention B)
Number of subjects: 0
Study: 17146393

Group type: EXPERIMENTAL
Intervention: GJB2 group (individuals with biallelic GJB2 mutations)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: GJB2 group
Number of subjects: 53

Group type: COMPARATOR
Intervention: Normally hearing individuals (control group)
Number of subjects: 53
Study: 12665988

Group type: EXPERIMENTAL
Intervention: Cycling (CYC)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Running (RUN)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 7
Study: 11052438

Group type: COMPARATOR
Intervention: Isoflurane, 0 to 1% plus fentanyl, 0.1 microg/kg/min
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ketamine, 0 to 5 mg/kg/h plus fentanyl, 0.1 microg/kg/min
Number of subjects: 50
Study: 9055774

Group type: EXPERIMENTAL
Intervention: Ultrasound detection of foreign bodies
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control punctures (no foreign bodies)
Number of subjects: 80
Study: 8140562

Group type: EXPERIMENTAL
Intervention: Selegiline (S) 10 mg/day
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 3315778

Group type: EXPERIMENTAL
Intervention: 200 mg daily for 3 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 600 mg in a single administration
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1000 mg in a single administration
Number of subjects: 60
Study: 29325772

Group type: EXPERIMENTAL
Intervention: Moderate carbohydrates diet
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 284
Study: 26973701

Group type: EXPERIMENTAL
Intervention: Choline supplementation (310 mg choline bitartrate twice daily for 6 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 24322628

Group type: EXPERIMENTAL
Intervention: Hyperpronation (HP)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Supination-Flexion (SF)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both maneuvers
Number of subjects: 115

Group type: COMPARATOR
Intervention: Prior manipulation
Number of subjects: 115
Study: 22503380

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 216
Study: 19439742

Group type: EXPERIMENTAL
Intervention: Epinephrine-dexamethasone group
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Epinephrine group
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Dexamethasone group
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 800
Study: 17954513

Group type: EXPERIMENTAL
Intervention: Intervention group (standardised protocol management with financial incentives)
Number of subjects: 951

Group type: COMPARATOR
Intervention: Control group (normal management without financial incentives)
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Intervention group (patients with positive malaria slides)
Number of subjects: 951
Study: 16353868

Group type: EXPERIMENTAL
Intervention: Neoton in combination with ischemic training
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard antianginal therapy
Number of subjects: 86
Study: 12370998

Group type: EXPERIMENTAL
Intervention: Management of patients with lung disease caused by RGM
Number of subjects: 0
Study: 9657222

Group type: EXPERIMENTAL
Intervention: Liquid-liquid extraction (LLE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated on-line solid-phase extraction (on-line SPE)
Number of subjects: 0
Study: 7655128

Group type: EXPERIMENTAL
Intervention: ivpb (intravenous piggyback) infusion of tobramycin sulfate 2 mg/kg at 100 mL/h for 30 minutes
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: slow CRIS (controlled-release infusion system) using a 20-mL vial at 60 mL/h for 1 hour
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: fast CRIS using a 20-mL vial at 120 mL/h for 1 hour
Number of subjects: 8
Study: 2247914

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 65606

Group type: EXPERIMENTAL
Intervention: Lactose hydrolysed milk
Number of subjects: 35

Group type: COMPARATOR
Intervention: Normal milk
Number of subjects: 35
Study: 30854751

Group type: EXPERIMENTAL
Intervention: Bilateral rTMS (low-frequency 1 Hz right DLPFC followed by high-frequency 10 Hz left DLPFC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Unilateral HFL rTMS
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 43
Study: 28528015

Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive behavior therapy (CBT)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Behavioral stress management (BSM)
Number of subjects: 158
Study: 24801119

Group type: EXPERIMENTAL
Intervention: MiStent absorbable polymer sirolimus‐eluting stent (APSES)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Zotarolimus‐eluting stent (ZES)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Both stents
Number of subjects: 184
Study: 23901280

Group type: EXPERIMENTAL
Intervention: Low-fat dairy (one serving/day each of 1% fluid milk, low-fat cheese, and low-fat yogurt)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Nondairy products (one serving/day each of apple juice, pretzels, and cereal bar)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Low-fat dairy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Nondairy products
Number of subjects: 62
Study: 21522030

Group type: EXPERIMENTAL
Intervention: HIV risk reduction program
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Socioeconomic disadvantage measures (percentage of years in the United States)
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Socioeconomic disadvantage measures (education)
Number of subjects: 548
Study: 20053240

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) delivered by a computer or therapist
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Therapist BI
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Computer BI
Number of subjects: 533

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 533
Study: 16954552

Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET
Number of subjects: 131
Study: 15737849

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 12738896

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for appropriate reasons
Number of subjects: 2124

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for uncertain reasons
Number of subjects: 2124

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for inappropriate reasons
Number of subjects: 2124

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy in symptomatic patients
Number of subjects: 2124

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy in asymptomatic patients
Number of subjects: 2124

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy in patients having combined carotid and coronary artery bypass graft surgery
Number of subjects: 2124

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy in asymptomatic patients with high comorbidity
Number of subjects: 2124
Study: 10430109

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aspirin (1000 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7565947

Group type: EXPERIMENTAL
Intervention: Fialuridine at a dose of either 0.10 or 0.25 mg per kilogram of body weight per day for 24 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fialuridine
Number of subjects: 15
Study: 2164771

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302

Group type: COMPARATOR
Intervention: Cimetidine 400 mg at bedtime
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Allopurinol (50 mg qds)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: DMSO (500 mg qds)
Number of subjects: 302
Study: 7028045

Group type: EXPERIMENTAL
Intervention: 5.6‐benzo‐alpha‐pyron + 3',4',7‐tris‐(hydroxy‐ethyl)‐rutin (coumarin + troxerutin, Venalot) at 1 mg/kg/d related to the coumarin content
Number of subjects: 560

Group type: COMPARATOR
Intervention: Coumarin and troxerutin applied separately
Number of subjects: 560
Study: 31150552

Group type: EXPERIMENTAL
Intervention: Schizophrenia-associated SNPs
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Protective allele SNPs
Number of subjects: 105
Study: 31155870

Group type: EXPERIMENTAL
Intervention: Plum-blossom needle tapping plus moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pelvic muscular exercise and passive intermittent urethral catheterization (Control)
Number of subjects: 60
Study: 28209607

Group type: EXPERIMENTAL
Intervention: IY Autistic Spectrum and Language Delays (IY‐ASLD) parent programme
Number of subjects: 72

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 72